Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Peter Verboven"'
Autor:
Loeckie De Zwart, Jan Snoeys, Frank Jacobs, Lilian Y. Li, Italo Poggesi, Peter Verboven, Ivo Goris, Ellen Scheers, Inneke Wynant, Mario Monshouwer, Rao N. V. S. Mamidi
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1107-1118 (2021)
Abstract Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid gl
Externí odkaz:
https://doaj.org/article/8775373d94c14cc6bf4c7d8ef15cfec3
Publikováno v:
Energies, Vol 9, Iss 3, p 195 (2016)
This paper studies the scalability and replicability of smart grid projects. Currently, most smart grid projects are still in the R&D or demonstration phases. The full roll-out of the tested solutions requires a suitable degree of scalability and rep
Externí odkaz:
https://doaj.org/article/43c6229102bc4edcbed4fe3ebe27dac2
Autor:
Thomas N. Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard‐Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Publikováno v:
The Journal of Clinical Pharmacology. 63:732-741
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cba13bd19fd72820553526ce012f9e1d
https://doi.org/10.1002/jcph.2214
https://doi.org/10.1002/jcph.2214
Autor:
Frank Jacobs, Loeckie de Zwart, I. Goris, Mario Monshouwer, Rao N.V.S. Mamidi, Lilian Y. Li, Italo Poggesi, Jan Snoeys, Peter Verboven, Ellen Scheers, Inneke Wynant
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1107-1118 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1107-1118 (2021)
Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abbc9d1666772a5a4609f5ea1cec529
https://doi.org/10.1002/psp4.12682
https://doi.org/10.1002/psp4.12682
Autor:
Stephanie Kourula, Merel Derksen, Ferran Jardi, Sophie Jonkers, Marjolein van Heerden, Peter Verboven, Veronique Theuns, Stijn Van Asten, Tinne Huybrechts, Annett Kunze, Ewa Frazer-Mendelewska, Ka Wai Lai, René Overmeer, Jamie Lee Roos, Robert G.J. Vries, Sylvia F. Boj, Mario Monshouwer, Farzin Pourfarzad, Jan Snoeys
Publikováno v:
European Journal of Pharmaceutical Sciences. :106481
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff41ba60f7d0e6a9dd68fb5df1bd0f7
https://doi.org/10.1016/j.ejps.2023.106481
https://doi.org/10.1016/j.ejps.2023.106481
Autor:
Yasuyoshi Iso, Shigeru Ando, Harrie J.M. Gijsen, Yasuto Kido, Shinji Suzuki, Herman Borghys, Kenji Morimoto, Vijay Urmaliya, Deborah Dhuyvetter, Takahiko Yamamoto, Ard Teisman, Gaku Sakaguchi, Naoki Kanegawa, Nigel Austin, Eriko Matsuoka, An Van Den Bergh, Hisanori Ito, Takuya Oguma, Francois Paul Bischoff, Tamio Fukushima, Peter Verboven, Tomoyuki Kawachi, Kenji Nakahara, Yoshinori Yamano, Kosuke Anan, Ken-ichi Kusakabe
Publikováno v:
ChemMedChem. 14:1894-1910
The β-site amyloid precursor protein cleaving enzyme 1 (BACE1, also known as β-secretase) is a promising target for the treatment of Alzheimer's disease. A pKa lowering approach over the initial leads was adopted to mitigate hERG inhibition and P-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985639c1cf0555b69c371d024a0d30ea
https://doi.org/10.1002/cmdc.201900478
https://doi.org/10.1002/cmdc.201900478
Autor:
James Jiao, Robert Stonerock, Caly Chien, Thomas Marbury, Peter Verboven, Jim Breeding, Namphuong Tran, Eric Lawitz, C. M. Haqq, Hans Stieltjes, Martha Gonzalez, Margaret K. Yu, Arturo Molina, Milin Acharya
Publikováno v:
The Journal of Clinical Pharmacology. 54:732-741
Three open-label, single-dose studies investigated the impact of hepatic or renal impairment on abiraterone acetate pharmacokinetics and safety/tolerability in non-cancer patients. Patients (n = 8 each group) with mild/moderate hepatic impairment or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9bbf1335eaa50c73035ebc8e945c857
https://doi.org/10.1002/jcph.253
https://doi.org/10.1002/jcph.253
Autor:
Jan Snoeys, Ellen Scheers, David C. Evans, Carlo Sensenhauser, Heng-Keang Lim, Laurent Leclercq, Peter Verboven, Shannon Dallas, Michael F. Kelley, Mark D. Johnson, Filip Cuyckens, Rao N.V.S. Mamidi
Aims Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed. Methods DDI potential of canagliflozin was investigated using in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2c9abf5fb872c233c8c45485ac3e9b
https://europepmc.org/articles/PMC5401984/
https://europepmc.org/articles/PMC5401984/
Autor:
James Witek, Varun Garg, Jan Snoeys, Petra Vinck, Rolf van Heeswijk, Els De Paepe, Griet Boogaerts, Ann Vandevoorde, Rodica Van Solingen-Ristea, Peter Verboven
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2304-2309
Hepatitis C virus (HCV) antibody is present in most patients enrolled in methadone maintenance programs. Therefore, interactions between the HCV protease inhibitor telaprevir and methadone were investigated. The pharmacokinetics of R- and S -methadon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048899099e56755de1c1379d5dd50e89
https://doi.org/10.1128/aac.02262-12
https://doi.org/10.1128/aac.02262-12
Publikováno v:
Energies, Vol 9, Iss 3, p 195 (2016)
Energies; Volume 9; Issue 3; Pages: 195
Energies; Volume 9; Issue 3; Pages: 195
This paper studies the scalability and replicability of smart grid projects. Currently, most smart grid projects are still in the R&D or demonstration phases. The full roll-out of the tested solutions requires a suitable degree of scalability and rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd110e2e61355576ece98f8403a6ee00
https://hdl.handle.net/11250/2397332
https://hdl.handle.net/11250/2397332